Ibandronic acid

Ibandronic acid
Clinical data
Trade names	Boniva, Bonviva, Bondronat, others
AHFS/Drugs.com	Monograph
License data	EU EMA: by INN; US DailyMed: Ibandronate_sodium; US FDA: Ibandronate_sodium;
Pregnancy; category	AU: B3; ;
Routes of; administration	By mouth, intravenous
ATC code	M05BA06 (WHO) ;
Legal status
Legal status	US: ℞-only; EU: Rx-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	0.6%
Protein binding	90.9 to 99.5%; (concentration-dependent)
Metabolism	Nil
Elimination half-life	10 to 60 hours
Excretion	Kidney
Identifiers
	IUPAC name Hydroxy-[1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl]phosphinate;
CAS Number	114084-78-5 ;
PubChem CID	60852;
IUPHAR/BPS	3059;
DrugBank	DB00710 ;
ChemSpider	54839 ;
UNII	UMD7G2653W;
KEGG	D08056 ; as salt: D04486 ;
ChEBI	CHEBI:93770;
ChEMBL	ChEMBL997 ;
PDB ligand	BFQ (PDBe, RCSB PDB);
CompTox Dashboard (EPA)	DTXSID5048340 ;
ECHA InfoCard	100.214.537
Chemical and physical data
Formula	C9H23NO7P2
Molar mass	319.231 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=P(O)(O)C(O)(CCN(CCCCC)C)P(=O)(O)O;
	InChI InChI=1S/C9H23NO7P2/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17) ; Key:MPBVHIBUJCELCL-UHFFFAOYSA-N ;
	(what is this?) (verify)

Ibandronic acid is a bisphosphonate medication used in the prevention and treatment of osteoporosis and metastasis-associated skeletal fractures in people with cancer.^[4] It may also be used to treat hypercalcemia (elevated blood calcium levels). It is typically formulated as its sodium salt ibandronate sodium.^{[medical citation needed]}

It was patented in 1986 by Boehringer Mannheim and approved for medical use in 1996.^[5]

^ "Bondronat EPAR". European Medicines Agency (EMA). 25 June 1996. Retrieved 28 August 2024.
^ "Bonviva EPAR". European Medicines Agency (EMA). 23 February 2004. Retrieved 28 August 2024.
^ "Iasibon EPAR". European Medicines Agency (EMA). 21 January 2011. Retrieved 30 August 2024.
^ Bauss F, Schimmer RC (March 2006). "Ibandronate: the first once-monthly oral bisphosphonate for treatment of postmenopausal osteoporosis". Therapeutics and Clinical Risk Management. 2 (1): 3–18. PMC 1661644. PMID 18360577.
^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 523. ISBN 9783527607495.